FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


FJ EXPRESS SUMMARY ARTICLE
The
Full-length version of this article is also available, published online July 24, 2000 as doi:10.1096/fj.99-0892fje.
Published as doi: 10.1096/fj.99-0892fje.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
14/12/1680
99-0892fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SI-HOE, S.-L.
Right arrow Articles by MURPHY, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SI-HOE, S.-L.
Right arrow Articles by MURPHY, D.
(The FASEB Journal. 2000;14:1680-1684.)
© 2000 FASEB

Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene

S.-L. SI-HOE*,{dagger}, F. M. DE BREE*, M. NIJENHUIS{ddagger}, J. E. DAVIES*, L. M. C. HOWELL*, H. TINLEY*, S. J. WALLER{dagger}, Q ZENG{dagger}, R. ZALM{ddagger}, M. SONNEMANS§, F. W. VAN LEEUWEN§, J. P. H. BURBACH{ddagger} and D. MURPHY*,{dagger}1

* Molecular Neuroendocrinology Research Group, Department of Medicine, University of Bristol, Bristol Royal Infirmary, Bristol BS2 8HW, U.K.;
{dagger} Neuropeptide Laboratory, Institute of Molecular and Cell Biology, Singapore 117609, Republic of Singapore;
{ddagger} Rudolf Magnus Institute for Neuroscience, Department of Medical Pharmacology, 3584 CG Utrecht, The Netherlands; and
§ Netherlands Institute for Brain Research, 1105 AZ, Amsterdam, The Netherlands

1Correspondence: Molecular Neuroendocrinology Research Group, Department of Medicine, University of Bristol, Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, U.K. E-mail d.murphy{at}bristol.ac.uk

SPECIFIC AIM

To test hypotheses regarding the etiology of dominant autosomal familial neurohypophyseal diabetes insipidus (FNDI) in new transgenic rat models.

PRINCIPAL FINDINGS

1. Human familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant endocrine disorder that presents in early childhood as excessive drinking and urination as a consequence of a progressive loss of secretion of vasopressin (VP) from posterior pituitary nerve terminals.

2. Mutations in the VP gene have been implicated as the cause of FNDI, but the mechanisms by which these mutants manifest their pathology and prevent the secretion of the coexpressed wild-type protein are unknown.

3. One hypothesis suggests that mutant precursors are toxic and stop the synthesis of wild-type VP by killing expressing cells. Another hypothesis suggests that aberrant interactions between mutant and wild-type precursors might inhibit the elaboration or secretion of the products of the normal allele.

4. We have tested these hypotheses using new transgenic rat models that express an FNDI mutant VP gene (3-VCAT-3-Cys67stop; Fig. 1c ) encoding a truncated VP precursor (Cys67stop).



View larger version (62K):
[in this window]
[in a new window]
 
Figure 1. 3-VCAT-3 Cys67stop transgenic rats. a) Structure of the rat VP-oxytocin (OT) genes and of the proteins they encode. The VP and OT genes are closely linked, tail-to-tail, in the rat genome, being separated by an intergenic region of 11 kbp that contains a LINE element. The VP gene encodes a prepropeptide consisting of, from the amino terminus, the signal peptide (SP), the VP nonapeptide itself, the disulfide-rich neurophysin (NP-II) moiety, and a 39 amino acid glycopeptide (copeptin; CPP). The OT gene encodes a precursor with a similar structure, except for the absence of CPP. NPs are known to be involved in three types of noncovalent interaction: hormone binding, dimerization (which is greatly facilitated by hormone binding), and further aggregation; through these interactions, the NPs are thought to play a role in the sorting of the prohormone into the secretory granule from the trans-Golgi network (TGN), and in intragranular processing and storage of hormone. The recognition sites of specific antisera (PS41 and PS60) are shown. b) Structure of 3-VCAT-3. Transgene 3-VCAT-3 consists of the rat VP structural gene containing a chloramphenicol acetyl transferase (CAT) reporter in exon III, flanked by 3 kbp of upstream and 3 kbp of downstream sequences. The transgene encodes a modified prepropeptide in which CPP is truncated, the carboxyl-terminal 26 amino acids being replaced with a novel epitope tag (DR-12-EK). 3-VCAT-3 is expressed in VP magnocellular neurons of the PVN and SON, within which it is subject to dramatic osmotic regulation. c) Structure of 3-VCAT-3-Cys67stop. Transgene 3-VCAT-3-Cys67stop was derived from 3-VCAT-3. A C to A transition replaces a Cys (TGC) at position 67 of NP-II with a translation termination codon (TGA). The recognition site of an antibody (CX67) that specifically recognizes the exposed carboxyl terminus of the Cys67stop mutant protein is shown. d) Dark-field image of in situ hybridization analyses of transgene expression in 3-VCAT-3-Cys67stop transgenic rats. Coronal brain sections from euhydrated (Control) transgenic rats or rats dehydrated for 3 days (Dehydration) were probed with a labeled oligonucleotide that hybridizes to the CAT component of the transgene RNA. Little expression is observed in control animals. In contrast, robust expression is seen in PVN and SON of dehydrated rats. e) Transgene RNA is translated into a peptide that accumulates in the cell bodies of hypothalamic magnocellular neurons. Coronal brain sections from 3-VCAT-3-Cys67stop rats dehydrated for 3 days were incubated with antisera specific for the endogenous wild-type NP-II (PS41) or the transgene peptide Cys67stop (CX67). CX67 reveals abundant peptide in the neuronal cell bodies of both the SON and PVN. In contrast, NP-II-like immunoreactivity is found in axons and cell bodies. f) Transient, inducible FNDI in Cys67stop transgenic rats. Wild-type (WT; n=4) and 3-VCAT-3-Cys67stop transgenic rats (TG; n=4) were housed in metabolic cages and subjected to CID. Water intake and urine output were monitored during the recovery phases. Data is shown ±SE. Significance (P<=0.05) is shown by an asterisk.

5. In situ hybridization (Fig. 1d ) revealed appropriate cell-specific expression of the transgene in hypothalamic magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN). Transgene transcript levels were dramatically induced by the physiological stimulation of dehydration.

6. The transgene RNA is translated into a peptide that can be detected in SON and PVN cell bodies, but not processes, of dehydrated rats using a specific antibody that recognizes the unique exposed carboxyl-terminal epitope found in the truncated Cys67stop precursor (Fig. 1e ).

7. Rats were assessed for effects of transgene expression on water balance using a protocol that ensured sustained transgene induction. After 6 cycles of chronic intermittent dehydration (CID; a CID cycle consists of 72 h of complete fluid deprivation followed by 96 h of rehydration), the 3-VCAT-3-Cys67stop rats drank significantly more and produced significantly more urine than control animals (Fig 1f ).

8. Cell-specific and -inducible expression of the Cys67stop mutation in rat VP hypothalamic neurons does not result in cell death or atrophy.

9. Expression of the FNDI mutant causes a neuronal pathology characterized by distorted structures in the cell body (Fig. 2a ) that are labeled by antisera that recognize endoplasmic reticulum (ER) markers (Fig. 2b ), and that accumulate mutant gene products (Fig. 2a, b ).



View larger version (35K):
[in this window]
[in a new window]
 
Figure 2. Subcellular pathology in 3-VCAT-3-Cys67stop hypothalamic neurons. a) Phase contrast microscopy reveals unusual perinuclear structures (bold arrow) that contain abundant Cys67stop peptide as revealed by the CX67 antiserum. b) The perinuclear structure is a deranged ER, within which the ER marker protein disulfide isomerase (recognized by 1D3) and Cys67stop (recognized by CX67) colocalize (yellow). Upper panel: high magnification (x216) showing two magnocellular neurons, one with the accretions and one without, but both showing colocalization (yellow). Lower panel: low magnification (x16) showing colocalization (yellow) of Cys67stop and the ER marker throughout the entire SON. c) Up-regulation of a lysosomal marker in SON of dehydrated 3-VCAT-3-Cys67stop rats. Little MPR immunoreactivity can be detected in control wild-type and transgenic rats or in wild-type rats after 7 CID cycles. However, abundant immunoreactivity is observed in the SON of transgenic rats after 7 CID cycles. d) Cys67stop expression elicits lysosome up-regulation. Increased lysosomal immunoreactivity is present in magnocellular neurons expressing the wild-type VP prohormone. Upper panel: high magnification (x216) showing a magnocellular neuron expressing NP-II (detected by PS41) and showing colocalization with the MPR marker. Lower panel: lower magnification (x64) showing a field of NP-II-expressing cells, most of which also contain abundant MPR immunoreactivity. (r) red; (g) green

10. Two ER phenotypes were evident (Fig. 2b ). The first was characterized by a diffuse ER staining that colocalized with Cys67stop-like immunoreactivity. The second phenotype was distinguished by a swollen and distorted ER packed with Cys67stop protein and endogenous VP. Transmission electron microscopy studies revealed that these bodies were delimited by a thick membrane and contained structurally intact ER and aggregates of mutant protein, and may represent preautophagic vesicles.

11. Intracellular pathology is accompanied by an increase in the abundance of the mannose-6-phosphate receptor (MPR), a marker of endosome-lysosome activity (Fig. 2c, d ).

CONCLUSIONS AND SIGNIFICANCE

Any hypothesis that seeks to explain the etiology of FNDI must address its dominant and progressive nature. The two current hypotheses are not entirely consistent with clinical and experimental observations. The first hypothesis suggests that aberrantly folded mutant protein may be toxic to the cell. We could find no evidence of atrophy or apoptosis in transgenic rats. Whereas neuronal atrophy might be a long-term consequence in some cases of FNDI, it is probably not the primary cause of the disease. The second hypothesis suggests that heterodimerization of mutant with wild-type precursors might disrupt the elaboration of VP gene products. However, this is difficult to reconcile with the progressive nature of the disease, and it has been shown that there is in fact little specific interaction between wild-type and Cys67stop precursors. Based on our new evidence, we suggest that FNDI may be initiated by the trapping of wild-type VP gene products within an ER that is targeted for lysosomal degradation by autophagy. A schematic diagram illustrating this process is shown in Fig. 3 .



View larger version (37K):
[in this window]
[in a new window]
 
Figure 3. Schematic diagram. Model for the quality control mechanisms and degradative pathway that may affect the Cys67stop mutant protein. After import into the ER, Cys67stop mutant protein is retained primarily by the thiol-mediated retention quality control mechanism due to presence of an unpaired Cys residue at position 61 of the NP-II moiety. Despite not being glycosylated, misfolded mutant prohormone may also be retained by an association with calnexin/calreticulin (only calnexin is shown in the diagram) via a protein–protein interaction. Nonspecific disulfide shuffling and cross-linking between thiol-retained Cys67stop mutant with wild-type VP prohormone in an intermediate folding stage may lead to the formation of inappropriate aggregates, which accumulate in the ER. Some mutant prohormone is probably re-exported from the ER for selective disposal by the ubiquitin-linked proteasomal pathway, without interrupting the normal transport of wild-type prohormone into the regulated secretory pathway. However, the eventual buildup of misfolded aggregates in a deranged ER activates a lysosomal-linked autophagic pathway that destroys the anomalous structure and consequently eliminates both mutant and wild-type VP. Abbreviations: QC, quality control; ER, endoplasmic reticulum.

Magnocellular neurons expressing the Cys67stop transgene develop a subcellular pathology characterized by a grossly distorted ER that accumulates both mutant and wild-type NP-II. The Cys67stop protein is probably retained in the ER by thiol retention, which involves disulfide interchange interactions with matrix proteins. Mutant Cys67stop possesses an unpaired Cys at residue 61 that is likely to be exposed and is eminently vulnerable to participation in disulfide interchanges. Mutations that result in uneven numbers of Cys residues can also subject other proteins to thiol retention. The Cys67stop protein may be involved in intermolecular disulfide bonding with other mutant VP prohormones presenting an exposed Cys 61 or with wild-type prohormones at an intermediate folding stage when disulfide interchanges are reversible. Thus, whereas there is no evidence for specific interactions between wild-type and mutant NPs, nonspecific disulfide interactions, leading to the formation of inappropriate nonselective aggregates, cannot be ruled out. Thus might the Cys67stop protein be responsible for the trapping of the wild-type VP precursor in the ER.

Proteins that have been retained in the ER are targeted for degradation. Two pathways are available: the autophagic lysosomal-endosomal pathway, and the proteasome system. Most substrates, including a majority of the ER retained proteins, are marked for proteasomal degradation by covalent linkage to multiple molecules of ubiquitin. There is prominent ubiquitin staining in the SON of dehydrated wild-type and transgenic rats, but transgenesis does not alter the staining pattern (not shown). The mutant protein is thus probably selectively targeted to the normally functioning cytosolic proteasome system, leaving most of the wild-type protein intact and capable of being delivered through the secretory pathway.

In contrast, autophagy is a nonselective bulk process whereby whole regions of cytoplasm become enveloped to form closed vacuoles, from which the sequestered material is subsequently delivered to lysosomes for degradation. Sequestration is energy dependent and starts with the formation of double-membrane sheets, possibly derived from the ribosome-free regions of the ER or the Golgi cisternae. Acidification of the autophagic vacuole is accomplished by acquisition or activation of an H+-ATPase, after which acid hydrolases are delivered, either by MPR-mediated transfer from endosomes or fusion with preexisting MPR deficient lysosomes. The increased number of MPR-positive endosomal compartments in chronically stimulated transgenic rats demonstrates a marked activation of the endosomal-lysosomal system, and we suggest that this correlates with increased autophagy.

We propose a new hypothesis to explain how the expression of a mutant FNDI allele can cause the loss of hormone production in VP neurons that continue to express the wild-type gene (Fig. 3) . The mutant Cys67stop possesses an unpaired Cys residue that will result in capture in the ER, probably by the thiol retention quality control system. The captive mutant protein is likely to be targeted to the cytosolic ubiquitin-proteasome system, leaving the wild-type protein intact and capable of being delivered through the secretory pathway. However, as mutant proteins accumulate in the ER, aggregates will form that will also contain wild-type molecules, trapped by aberrant disulfide-bond interactions with Cys67stop. This results in the development of a subcellular pathology characterized by a grossly distorted ER that accumulates both mutant and wild-type NP-II. We propose that under these circumstances, the selective degradation system cannot cope, and a more general degradation system—autophagy—is activated to remove the deranged ER. Wild-type prohormone will be eliminated when the deranged organelle is destroyed, resulting in VP deficiency.

FOOTNOTES

To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.99-0892fje




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. H. Christensen, C. Siggaard, T. J. Corydon, G. L. Robertson, N. Gregersen, L. Bolund, and S. Rittig
Differential Cellular Handling of Defective Arginine Vasopressin (AVP) Prohormones in Cells Expressing Mutations of the AVP Gene Associated with Autosomal Dominant and Recessive Familial Neurohypophyseal Diabetes Insipidus
J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4521 - 4531.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Nijenhuis, E. L. T. van den Akker, R. Zalm, A. A. M. Franken, A. P. Abbes, H. Engel, D. de Wied, and J. P. H. Burbach
Familial Neurohypophysial Diabetes Insipidus in a Large Dutch Kindred: Effect of the Onset of Diabetes on Growth in Children and Cell Biological Defects of the Mutant Vasopressin Prohormone
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3410 - 3420.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
14/12/1680
99-0892fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SI-HOE, S.-L.
Right arrow Articles by MURPHY, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SI-HOE, S.-L.
Right arrow Articles by MURPHY, D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS